FDA Approves Nivolumab/Ipilimumab in Adult/Pediatric MSI-H or dMMR CRC

Fact checked by" Russ Conroy
News
Article

The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.

Data from the phase 3 CheckMate 8HW trial (NCT04008030) supported the FDA approval of nivolumab plus ipilimumab in unresectable or metastatic MSI-H or dMMR colorectal cancer.

Data from the phase 3 CheckMate 8HW trial (NCT04008030) supported the FDA approval of nivolumab plus ipilimumab in unresectable or metastatic MSI-H or dMMR colorectal cancer.

The FDA has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), according to a press release from the FDA.1

Addiitonally, the FDA converted the accelerated approval for single-agent nivolumab to a normal approval for adult and pediatric patients with MSI-H or dMMR metastatic CRC who progressed on fluoropyrimidine, oxaliplatin, and irinotecan.

Supporting results come from the randomized, phase 3 CHECKMATE-8HW trial (NCT04008030) that evaluated nivolumab with ipilimumab in immunotherapy-naïve patients with CRC with known MSI-H or dMMR status.

The median progression-free survival (PFS) in the first-line setting was not reached (NR; 95% CI, 38.4-not estimable [NE]) with nivolumab plus ipilimumab vs 5.8 months (95% CI, 4.4-7.8) with chemotherapy (HR, 0.21; 95% CI, 0.14-0.32; P <.0001). At the time of interim PFS analysis, comparable results for overall response rate (ORR) and overall survival (OS) in the first-line setting were not available.

In all lines of treatment, the median PFS was NR (95% CI, 53.8-NE) with nivolumab and ipilimumab vs 39.3 months (95% CI. 22.1-NE) with chemotherapy (HR, 0.62; 95% CI. 0.48-0.81; P = .0003). The ORR was 71% (95% CI, 65%-76%) vs 58% (95% CI, 52%-63%), respectively (P = .0011). Comparative results for OS were not available.

Adverse events reported in greater than 20% of patients with nivolumab and ipilimumab were fatigue, diarrhea, pruritus, abdominal pain, musculoskeletal pain, and nausea.

Reference

FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer. News release. FDA. April 8, 2025. Accessed April 8, 2025. https://tinyurl.com/3vj77rfh

Recent Videos
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content
FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC

Ariana Pelosci;Tim Cortese
April 11th 2025
Article

Results from the phase 3 CheckMate 9DW trial of nivolumab/ipilimumab vs lenvatinib or sorafenib led to the approval for patients with unresectable or metastatic HCC.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

Active Surveillance Shows Noninferior OS vs Surgery in Esophageal Cancer

Roman Fabbricatore
April 5th 2025
Article

Postoperative complications and mortality after standard or postponed surgery for esophageal cancer after active surveillance were similar in both groups.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

Tim Cortese
April 2nd 2025
Article

Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

Tim Cortese
March 31st 2025
Article

Muhammad Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.